GlassScriptPhysician profile
Cindy Phelps
NPI 1013466333
$2,050.74
in general payments reported to CMS, 2019-2025
28 companies · $627 in 2025
The $627 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.34 · 2023: $857 · 2024: $526 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $232.13 | 2023-2024 | |
| Amgen INC. | $226.97 | 2024-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $178.18 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $174.51 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.00 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.13 | 2023-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Exact Sciences Corporation | $79.71 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $66.26 | 2023-2024 | |
| Lucid Diagnostics INC. | $63.04 | 2023 | |
| Esperion Therapeutics, INC. | $55.97 | 2021-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $53.65 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $51.83 | 2024-2025 | Voquezna |
| Pfizer INC. | $44.57 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $44.16 | 2023 | Seglentis, Livalo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $36.10 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $25.90 | 2023 | Aptima, Thinprep 2000 Processor |
| Mylan Specialty L.P. | $24.75 | 2023 | Yupelri |
| Dynavax Technologies Corporation | $24.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.24 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $23.91 | 2023 | |
| Cequr Corporation | $23.19 | 2023 | Cequr Simplicity |
| Astellas Pharma US INC | $22.22 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $21.05 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Corcept Therapeutics | $19.80 | 2025 | Korlym |
| Dexcom, INC. | $15.97 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $15.04 | 2025 | Shingrix |
| Tactile Systems Technology INC | $13.82 | 2024 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.